WASHINGTON — The Biden administration announced last Tuesday it’s reinterpreting federal law to allow Medicare and Medicaid patients access to anti-obesity medications to reduce their weight over the ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

The bipartisan legislation could affect 275 drugs, everything from the supply of weight-loss drugs to the supply of ...

Sanofi just made its largest investment thus far in China. The company has committed just over $1 billion to build a new ...

Amgen's new obesity drug, MariTide, shows promise against giants Eli Lilly and Novo Nordisk, but faces tough competition in a ...

Doctors say early obesity intervention can help prevent later health problems. But prescribing GLP-1s, such as Ozempic and ...

Ozempic, Wegovy, and other weight-loss drugs could make millions healthier, but access and affordability barriers abound.

State measures now seek to remove barriers to weight-loss drugs, as demand for the meds skyrockets amid rising concerns about ...

Novo Nordisk is working to accelerate the launch of its weight-loss drug Wegovy in India, concerned about lagging behind Eli ...

Novo Nordisk's team in India has been pushing the Danish drugmaker's global leadership for an earlier launch of its popular ...

The future of obesity treatment looks highly promising with the development of next generation therapies. There are currently 79 clinical stage programmes across at least 41 unique mechanisms of ...

The ADA recommended doctors avoid prescribing unapproved, off-brand versions of drugs like Wegovy, wading into a dispute that ...